{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:14:19Z","timestamp":1789154059536,"version":"build-2803163510"},"reference-count":22,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270889","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:25:13Z","timestamp":1762449913000},"page":"4-11","source":"Crossref","is-referenced-by-count":5,"title":["Rechallenge and Extended [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA Therapy in Metastatic Prostate Cancer"],"prefix":"10.2967","volume":"67","author":[{"given":"Seyed Ali","family":"Mirshahvalad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sharifian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Manoochehry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundula","family":"Rendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Schweighofer-Zwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026010206300898000_67.1.4.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.12.019"},{"key":"2026010206300898000_67.1.4.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026010206300898000_67.1.4.3","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.3390\/cancers13246255","article-title":"Radiolabeled PSMA inhibitors","volume":"13","author":"Neels","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026010206300898000_67.1.4.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026010206300898000_67.1.4.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2026010206300898000_67.1.4.6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","article-title":"Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer","volume":"46","author":"Yordanova","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300898000_67.1.4.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215715"},{"key":"2026010206300898000_67.1.4.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06905-5"},{"key":"2026010206300898000_67.1.4.9","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.3390\/cancers15184605","article-title":"Intermittent radioligand therapy with 177Lu-PSMA-617 for oligometastatic castration-resistant prostate cancer","volume":"15","author":"Mader","year":"2023","journal-title":"Cancers (Basel)."},{"key":"2026010206300898000_67.1.4.10","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00259-024-06825-4","article-title":"Efficacy and safety of rechallenge [177Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)","volume":"51","author":"Rosar","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300898000_67.1.4.11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/ajco.13944","article-title":"Outcomes and prognostic predictors of Lu\u2010177 PSMA radioligand therapy in metastatic castration\u2010resistant prostate cancer (Asian population study)","volume":"20","author":"Chua","year":"2024","journal-title":"Asia Pac J Clin Oncol."},{"key":"2026010206300898000_67.1.4.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267321"},{"key":"2026010206300898000_67.1.4.13","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.3390\/cancers13102489","article-title":"Response and toxicity to the second course of 3 cycles of 177Lu-PSMA therapy every 4 weeks in patients with metastatic castration-resistant prostate cancer","volume":"13","author":"Rasul","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026010206300898000_67.1.4.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.236414"},{"key":"2026010206300898000_67.1.4.15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/MNM.0000000000001611","article-title":"Response to [177Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases","volume":"43","author":"Zisser","year":"2022","journal-title":"Nucl Med Commun."},{"key":"2026010206300898000_67.1.4.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264293"},{"key":"2026010206300898000_67.1.4.17","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","article-title":"Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer","volume":"50","author":"Mader","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300898000_67.1.4.18","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00259-025-07125-1","article-title":"Impact of extended [177Lu]Lu-PSMA-617 therapy on absorbed kidney dose and CKD-EPI values: how long can therapy be safely continued?","volume":"52","author":"Topal","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026010206300898000_67.1.4.19","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1097\/RLU.0000000000004222","article-title":"Outcome of 177Lu-PSMA radionuclide treatment in advanced prostate cancer and its association with clinical parameters: a single-center experience","volume":"47","author":"Simsek","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2026010206300898000_67.1.4.20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/ijc.34749","article-title":"The real\u2010world outcomes of lutetium\u2010177 PSMA\u2010617 radioligand therapy in metastatic castration\u2010resistant prostate cancer: Turkish Oncology Group multicenter study","volume":"154","author":"Almuradova","year":"2024","journal-title":"Int J Cancer."},{"key":"2026010206300898000_67.1.4.21","doi-asserted-by":"crossref","first-page":"TPS5110","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5110","article-title":"A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT)","volume":"42","author":"Holzgreve","year":"2024","journal-title":"J Clin Oncol."},{"key":"2026010206300898000_67.1.4.22","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/j.ijrobp.2024.07.1254","article-title":"Phase 2 prospective trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA): study protocol","volume":"120","author":"Nikitas","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:30:27Z","timestamp":1767364227000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270889"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270889","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}